Niraparib

The FDA expanded the approval of niraparib for gynecologic cancers.

The introduction of poly (ADP-ribose) polymerase, or PARP, inhibitors has made a significant impact in ovarian cancer, prolonging PFS among certain patients, particularly those with BRCA mutations.